Format

Send to

Choose Destination
Anticancer Res. 2019 Jul;39(7):3745-3755. doi: 10.21873/anticanres.13523.

Resveratrol Modulates the Redox-status and Cytotoxicity of Anticancer Drugs by Sensitizing Leukemic Lymphocytes and Protecting Normal Lymphocytes.

Author information

1
Faculty of Veterinary Medicine, Trakia University, Stara Zagora, Bulgaria.
2
Medical Faculty, Trakia University, Stara Zagora, Bulgaria.
3
Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria.
4
Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), Chiba, Japan.
5
Group of Quantum-state Controlled MRI, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.
6
Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), Chiba, Japan bakalova.rumiana@qst.go.jp.
7
Medical Faculty, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria.

Abstract

BACKGROUND/AIM:

The study is directed to the effect of resveratrol on the redox-status and viability of leukemic and normal lymphocytes, as well as its ability to sensitize leukemic lymphocytes to anticancer drugs.

MATERIALS AND METHODS:

Cytotoxicity was analyzed by trypan blue staining, apoptosis - by Annexin V test, and oxidative stress - by the intracellular levels of reactive oxygen species (ROS) and protein-carbonyl products.

RESULTS:

Incubation of resveratrol in combination with the majority of anticancer drugs resulted in higher toxicity than resveratrol or drug alone. In the case of leukemic lymphocytes treated with barasertib and everolimus in the presence of resveratrol, synergistic cytotoxicity was accompanied by strong induction of apoptosis, increased levels of hydroperoxides and insignificant changes in protein-carbonyl products. None of these parameters changed in normal lymphocytes.

CONCLUSION:

Resveratrol is a promising supplementary compound for anticancer therapy, that may allow reduction of the therapeutic doses of barasertib and everolimus, minimizing their side-effects.

KEYWORDS:

Cancer; apoptosis; chemotherapy; oxidative stress; resveratrol

PMID:
31262901
DOI:
10.21873/anticanres.13523
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center